Work

Do sodium-glucose cotransporter-2 inhibitors impact pulmonary symptoms in heart failure patients? A systematic literature review

Year: 2025

Type: review

Abstract: Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown promise for reducing adverse cardiovascular events in patients with heart failure. Our study looked at the effects of SGLT2 inhibitor use on pulmonary outcomes in patients with all types of heart failure. With comorbidities such as pulmonary hypertension in patients with heart failure, we looked at the evidence of pulmonary function in patients with heart failure through echocardiogram. Our study seeks to determine the use of SGLT2 inhibitors to alleviate pulmonary comorbidities in heart failure patients.

Source: SHAREOK (University of Oklahoma; Oklahoma State University; Central Oklahoma University)

Authors: Tanzey, Karlyn, Wilson, Jordan, Hazlitt, Rachel, Timmerman, Clint, Vassar, Matt

Language: English

Topic: Heart Failure Treatment and Management

Subfield: Cardiology and Cardiovascular Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7110501175

FWCI:

Cites:

Cited by:

Related to: